Cytochrome P450 2B6, Cytochrome P450 3A4, Cytochrome P450 2A6, and Cytochrome P450 2C9 (CYP2B6, CYP3A4, CYP2A6, CYP2C9)

The Cytochrome P450 (CYP) enzymes CYP2B6, CYP3A4, CYP2A6, and CYP2C9 are critical heme-thiolate monooxygenases primarily expressed in the liver that facilitate the Phase I metabolism of a wide range of medications and endogenous compounds (NIH: StatPearls). CYP3A4 is the most significant isoform, involved in the metabolism of approximately 50% of all clinical drugs, while CYP2C9 is essential for processing drugs with narrow therapeutic windows, such as warfarin and phenytoin (UniProt: P08684, P11712). CYP2B6 and CYP2A6 play specialized roles in the metabolism of antidepressants, antiretrovirals, and nicotine (UniProt: P20813, P11509). These enzymes are major determinants of drug bioavailability and are the primary site for clinically significant drug-drug interactions, where one drug may inhibit or induce the metabolism of another (FDA: Drug Development and Drug Interactions). Furthermore, significant genetic variability (polymorphisms) in these enzymes leads to diverse metabolic phenotypes, making them central to the field of pharmacogenomics and personalized medicine (PharmGKB). Understanding the activity and inhibition profiles of these specific CYP isoforms is a fundamental requirement in drug development to ensure patient safety and therapeutic efficacy.

Other names

CYP450Microsomal monooxygenasesHeme-thiolate proteinsCYP2B6CYP3A4CYP2A6CYP2C9

These enzymes catalyze the Phase I oxidative metabolism of drugs, typically via hydroxylation, N-dealkylation, or O-dealkylation, using molecular oxygen and electrons from NADPH-cytochrome P450 reductase (NIH: StatPearls). Drugs can act as substrates, or they can modulate enzyme activity as inhibitors (blocking the active site) or inducers (increasing enzyme synthesis via nuclear receptor pathways like PXR or CAR) (FDA: Drug Development and Drug Interactions).